Companies

Amplifold elevates rapid diagnostics to a new performance level. By integrating DNA origami nanostructures into conventional lateral flow tests, the company increases sensitivity by up to one hundred fold without requiring instruments or changes to manufacturing. This enables laboratory-level performance in a familiar strip-based format, opening new possibilities in infectious disease, oncology and decentralised testing.

Syntropic develops a non-invasive and non-pharmaceutical treatment for mental health disorders. Through light stimulation, neural remodeling is activated by instructing the immune cells of the brain to support in healing and recovery.

ONCO-Boost, the first product from HEPHAISTOS-Pharma’s platform, is a natural TLR4 agonist that stimulates the patients’ own immune system to strengthen both innate and adaptive immune systems to strengthen their responses against cold tumors.

Solgate’s founders combine deep expertise in the biology of solute carriers with unique chemistry-based approaches for accelerated drugging of difficult targets. Current projects are focused on CNS and immunology indications.

Sarcura set out to tackle one of the toughest challenges in advanced medicine: how to manufacture cell therapies at scale. With an interdisciplinary founders team and a research-derived, innovative product for a growing market, they aimed to miniaturize and automate cell therapy production on a chip.

At xista science ventures, we are proud to have supported this journey from its early days, providing capital, infrastructure, and a place in our community. While Sarcura will not continue as a company, it's achievements and people remain part of our ecosystem as a Retired Innovation Pioneer. This

Ribbon Biolabs is a synthetic biology leader driving DNA synthesis beyond the limits of current technologies. With their automated, enzyme-based platform, Ribbon Biolabs can provide synthetic DNA molecules without size or sequence limitations at a high level of accuracy and at unprecedented speed.

G.ST Antivirals is a clinical-stage biotech company that develops broad-spectrum antivirals against respiratory tract infections. Founded in 2019 by Guido Gualdoni and Johannes Stöckl, the company leverages an innovative host cell-based strategy to overcome respiratory viral infections. This approach is based on a high-impact paper on the interaction of a respiratory virus with the infected cell, which was published by the founders while working at the Medical University of Vienna.

The immune system protects our body against bacteria, viruses and other external threats to our health. Dendritic cells (DCs) play a central role by recognizing such pathogens, processing them and training other immune cells to act against them. At the same time, DCs are also responsible for tolerating the body’s own structures (autoantigens). This complex interaction is achieved by an „orchestra“ of different types of DCs. Cutanos aims to use these mechanisms to develop both vaccines and therapies against autoimmune diseases and allergies.

The cell is at the center of current and future biological science. Future trends require novel technologies to unlock their full potential. The combination of electrodynamics and biotechnology perfectly complements the requirements of emerging industries when it comes to efficient analysis and modulation of biological cells.

Brightmind.AI is developing therapeutic TMS (transcranial magnetic stimulation) devices for home use, with a first indication of migraine.

By means of synthetic biology and genetic code expansion Valanx has developed a novel site-specific protein conjugation platform that allows precise control over conjugation site and number of conjugations on the protein of interest. Based on this platform Valanx is developing a number of cutting-edge biologics towards potential treatments for various indications.

Artificial Intelligence (AI) is increasingly prevalent in business and society. An area where AI is performing well already is healthcare, with significant developments in early detection, diagnostics, decision making or workflow support providing clinical value.

Neurolentech is a spinoff of ISTA (Institute of Science and Technology Austria) focused on personalized medicine for neurodevelopmental disorders. The company is developing and characterizing libraries of patient-derived neuronal cells, and will leverage this unique resource for the development of novel therapeutics to tackle severe forms of autism and epilepsy.

Brainhero is a medtech company that is focused on unlocking and enhancing the potential of children with autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD). Their CE-certified neurofeedback therapy system, a Class IIa medical device (MDR), includes a wearable EEG device and user-friendly software, providing flexibility for their target audience.

Additionally, Brainhero is developing EEG technology for home-based diagnostic measures to detect neurological issues early. With a long-term vision, Brainhero aims to address a broader range of neurological impairments